Empreses emergents
2017
AHEAD THERAPEUTICS SLLLUITA DE LES MALALTIES AUTOIMMUNITARIES - La nanoteràpia basada en Bio-Mimicking Company va deixar d'activitat
Adreça
Via Laietana 26, 08003 Barcelona, Espanya
Dades financeres
Propietat CERCA
Badalona, Spain
1995
IGTP
Cerdanyola del Vallès, Spain
2004
Institut Català de Nanociència i Nanotecnologia (ICN2)
Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Ahead Therapeutics is a start-up biotech company that uses a proprietary technology to develop treatments for different auto-immune disorders.
Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, thereby interrupting the autoimmune reaction.
Simply by changing the encapsulated auto-antigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others.
Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, thereby interrupting the autoimmune reaction.
Simply by changing the encapsulated auto-antigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others.
Descripció del producte
To re-establish immune tolerance against self-tissues, AHEAD THERAPEUTICS S.L. has developed a technology based on bio-mimicking Efferocytosis, a crucial and well-known physiological process involved in ‘Antigen Specific Immune Tolerance Induction’, whereby apoptotic cells are removed from the body by being recognized, recruited and engulfed by immature dendritic cells (DCs).
Our technological platform contains a wide range of Liposomes based on Phosphatidylserine and other endogenous mammal compounds. These Liposomes are of a certain particle size and are accurately produced to encapsulate a specific Auto-antigen, depending on the illness to be treated.
By administering our Liposomes with Phosphatidylserine in the outer membrane, Apoptosis in cells is simulated to trigger the Efferocytosis mechanism and generate not only Specific Tolerance against the encapsulated Auto-antigen but also to induce immunological memory.
Furthermore, as our approach is not HLA dependent, personalized treatment is not required, adding a major economical advantage to the platform
Our technological platform contains a wide range of Liposomes based on Phosphatidylserine and other endogenous mammal compounds. These Liposomes are of a certain particle size and are accurately produced to encapsulate a specific Auto-antigen, depending on the illness to be treated.
By administering our Liposomes with Phosphatidylserine in the outer membrane, Apoptosis in cells is simulated to trigger the Efferocytosis mechanism and generate not only Specific Tolerance against the encapsulated Auto-antigen but also to induce immunological memory.
Furthermore, as our approach is not HLA dependent, personalized treatment is not required, adding a major economical advantage to the platform